Study to measure the effectiveness of the Budesonide/formoterol electronic multidose dry powder inhaler (BF Digihaler) Digital System (DS)

Study Title
CONNected Electronic Inhalers Asthma Control Trial 3 ("CONNECT 3"), a 24-Week Treatment, Multicenter, Open Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus the Budesonide/Formoterol Digihaler Digital System, to Optimize Outcomes in Adult Patients with Asthma
Teva Identifier
BFS-AS-40184
ClinicalTrials.gov Identifier
N/A
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: Budesonide/Formoterol Digihaler Digital System
EudraCT Number
2021-003951-41

Study Description

The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care group
Print

EudraCT Link


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
January 23, 2023 - June 29, 2023
Phase
Phase 4

Study Type

Interventional